Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Christie Low"'
Autor:
Chris H. Takimoto, Erika Martinelli, Allan van Oosterom, Eric Walk, Kathryn Parker, Margaret Dugan, Jerry Huang, Christie Low, William Mietlowski, Clifford DiLea, Josep Tabernero, Frederico Rojo, Herlinde Dumez, Patrick Schöffski, Alain C. Mita, José Baselga
PDF file - 59K, Pharmacodynamic Parameters
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91e14cb944d79c031c6011a979c8d4e6
https://doi.org/10.1158/1078-0432.22447530.v1
https://doi.org/10.1158/1078-0432.22447530.v1
Autor:
Chris H. Takimoto, Erika Martinelli, Allan van Oosterom, Eric Walk, Kathryn Parker, Margaret Dugan, Jerry Huang, Christie Low, William Mietlowski, Clifford DiLea, Josep Tabernero, Frederico Rojo, Herlinde Dumez, Patrick Schöffski, Alain C. Mita, José Baselga
PDF file - 56K, Mean Pharmacokinetic Parameters
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::727c4c0ce9450476bd0f0d51cbaf033a
https://doi.org/10.1158/1078-0432.22447533
https://doi.org/10.1158/1078-0432.22447533
Autor:
Chris H. Takimoto, Erika Martinelli, Allan van Oosterom, Eric Walk, Kathryn Parker, Margaret Dugan, Jerry Huang, Christie Low, William Mietlowski, Clifford DiLea, Josep Tabernero, Frederico Rojo, Herlinde Dumez, Patrick Schöffski, Alain C. Mita, José Baselga
PDF file - 72K, Most Frequent Adverse Events (≥ 15%, any dose group) by Initial Dose Group (Safety Population)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::372cae8dbd0011744274748a2a24fcfc
https://doi.org/10.1158/1078-0432.22447536
https://doi.org/10.1158/1078-0432.22447536
Autor:
Chris H. Takimoto, Erika Martinelli, Allan van Oosterom, Eric Walk, Kathryn Parker, Margaret Dugan, Jerry Huang, Christie Low, William Mietlowski, Clifford DiLea, Josep Tabernero, Frederico Rojo, Herlinde Dumez, Patrick Schöffski, Alain C. Mita, José Baselga
PDF file - 50K, Primary Antibodies Used for Immunohistochemical Staining
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::538b3b600179b1b5c819848bcd8092b1
https://doi.org/10.1158/1078-0432.22447539
https://doi.org/10.1158/1078-0432.22447539
Autor:
Chris H. Takimoto, Erika Martinelli, Allan van Oosterom, Eric Walk, Kathryn Parker, Margaret Dugan, Jerry Huang, Christie Low, William Mietlowski, Clifford DiLea, Josep Tabernero, Frederico Rojo, Herlinde Dumez, Patrick Schöffski, Alain C. Mita, José Baselga
Purpose: In this first-in-human study of AEE788, a tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR), HER-2, and VEGFR-2, a comprehensive pharmacodynamic program was implemented in addition to the evaluation of safety, pharmacokine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23fac8cfffc49db97f13c3f603843603
https://doi.org/10.1158/1078-0432.c.6521103
https://doi.org/10.1158/1078-0432.c.6521103
Autor:
Frederico Rojo, José Baselga, Herlinde Dumez, Eric Walk, Patrick Schöffski, Alain C. Mita, Allan T. van Oosterom, C. H. Takimoto, William Mietlowski, Josep Tabernero, Margaret Dugan, Kathryn Parker, Erika Martinelli, J. Huang, Christie Low, Clifford DiLea
Purpose: In this first-in-human study of AEE788, a tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR), HER-2, and VEGFR-2, a comprehensive pharmacodynamic program was implemented in addition to the evaluation of safety, pharmacokine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e7bf3b6ad6ae93381430e750006ac20
http://hdl.handle.net/11591/372601
http://hdl.handle.net/11591/372601